NASDAQ · DTSQ
Financial Services · Financial - Conglomerates
$11.30
Up+$0.03 (+0.27%)
Updated Aug 22, 2026, 4:19 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 8 trading sessions · Daily adjusted prices
DTSQ closed at $11.30 after 8 trading sessions, down 0.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $11.11 | $11.30 | $11.11 | $11.30 | 2.18K |
| Aug 10, 2026 | $11.26 | $11.26 | $11.26 | $11.26 | 344 |
| Aug 6, 2026 | $11.23 | $11.24 | $11.23 | $11.24 | 1.3K |
| Aug 5, 2026 | $11.26 | $11.27 | $11.26 | $11.27 | 1.84K |
| Aug 4, 2026 | $11.31 | $11.33 | $11.31 | $11.33 | 331 |
| Jul 30, 2026 | $11.32 | $11.32 | $11.32 | $11.32 | 220.4 |
| Jul 29, 2026 | $11.32 | $11.37 | $11.31 | $11.365 | 21.67K |
| Jul 24, 2026 | $11.32 | $11.35 | $11.32 | $11.35 | 229 |
The latest Smart Investors Daily articles mentioning DTSQ.
DTSQ research
Company profile and research snapshot.
DT Cloud Star Acquisition Corp is a blank check company.
Consensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jul 20, 2026
DT Cloud Star Acquisition Corporation (NASDAQ:DTSQU, DTSQ, DTSQR))) (the "Company") a newly organized blank check company incorporated in the Cayman Islands as a business company, today announced that on July
Yahoo · Feb 4, 2026
SANTA ANA, CALIFORNIA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- PrimeGen US, Inc. (“PrimeGen US" or the "Company”), a pioneering biotech company advancing innovative stem cell and exosome therapies, today announced it has entered into a definitive business combination agreement dated as of February 2, 2026 (the "Business Combination Agreement") with DT Cloud Star Acquisition Corporation (“DT Cloud Star”), a publicly traded special purpose acquisition company (Nasdaq: DTSQ). The transaction implies an e
Benzinga · Feb 4, 2026
Benzinga · Feb 4, 2026
PrimeGen US, Inc. ("PrimeGen US" or the "Company"), a pioneering biotech company advancing innovative stem cell and exosome therapies, today announced it has entered into a definitive business combination
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DTSQ.
